耐多药结核病患者密切接触者结核分枝杆菌潜伏感染的诊治现状与展望

doi:10.19983/j.issn.2096-8493.20220148

结核与肺部疾病杂志 ›› 2022, Vol. 3 ›› Issue (6): 517-520.doi: 10.19983/j.issn.2096-8493.20220148

耐多药结核病患者密切接触者结核分枝杆菌潜伏感染的诊治现状与展望

陈秋奇¹, 吴超玲², 张培泽³, 邓国防³()

1.广东医科大学研究生院,湛江 524023
2.赣南医学院第一临床医学院,赣州 341000
3.广东医科大学附属深圳市第三人民医院肺病二科,深圳 518112

收稿日期:2022-09-14 出版日期:2022-12-20 发布日期:2022-12-15
通信作者: 邓国防 E-mail:jxxk1035@yeah.net
基金资助:
国家自然科学基金(82070016);佛山市第四人民医院“登峰计划”高水平医院建设开放课题(FSSYKF-2020001);结核病宿主反应检测技术在肺结核疗效评价中的应用研究(G2022005);结核分枝杆菌体内异质性机制及其对结核病临床预后的影响研究(G2021015)

Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection

Chen Qiuqi¹, Wu Chaoling², Zhang Peize³, Deng Guofang³()

1. Graduate School of Guangdong Medical University, Guangdong Province, Zhanjiang 524023, China
2. The First Clinical Medical College of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China
3. The Second Department of Pulmonary Diseases, Shenzhen Third People’s Hospital Affiliated to Guangdong Medical University, Guangdong Province, Shenzhen 518112, China

Received:2022-09-14 Online:2022-12-20 Published:2022-12-15
Contact: Deng Guofang E-mail:jxxk1035@yeah.net
Supported by:
National Natural Science Foundation of China(82070016);Dengfeng Plan of Foshan Fourth People’s Hospital Construction of High Level Hospital Open Project(FSSYKF-2020001);Application of Tuberculosis Host Reaction Detection Technology in Evaluation of Curative Effect of Pulmonary Tuberculosis(G2022005);Study on the Heterogeneity Mechanism of Mycobacterium Tuberculosis and its Effect on the Clinical Prognosis of Tuberculosis(G2021015)

摘要/Abstract

摘要：

耐多药结核病患者的密切接触者感染耐多药结核分枝杆菌的风险较高,部分患者易罹患耐多药结核分枝杆菌相关的潜伏感染,是管控结核病的重点人群。目前,对耐多药结核分枝杆菌潜伏感染的筛查方法存在不足,预防性治疗的目标人群和治疗方案仍不完全明确。笔者就耐多药结核分枝杆菌潜伏感染的流行病学、筛查策略和预防性治疗策略等方面的进展进行综述,以加强临床医生的认识。

关键词: 结核, 抗多种药物性, 接触者追踪, 诊断, 治疗学

Abstract:

Close contacts with multidrug-resistant tuberculosis (MDR-TB) patients have a high risk of MDR-TB infection. Some of them are prone to develop latent MDR-TB infections so that they will become a key population for tuberculosis management and control. At present, the screening and treatment of latent MDR-TB infection are challenging and still unclear. Therefore, we reviewed the epidemic and the evidence of screening, management or prevention in close contact with MDR-TB.

Key words: Tuberculosis, multidrug-resistant, Contact tracing, Diagnosis, Therapeutics

中图分类号:

陈秋奇, 吴超玲, 张培泽, 邓国防. 耐多药结核病患者密切接触者结核分枝杆菌潜伏感染的诊治现状与展望[J]. 结核与肺部疾病杂志, 2022, 3(6): 517-520. doi: 10.19983/j.issn.2096-8493.20220148

Chen Qiuqi, Wu Chaoling, Zhang Peize, Deng Guofang. Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection[J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 517-520. doi: 10.19983/j.issn.2096-8493.20220148

参考文献 30

[1]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0. doi: 10.1016/S0140-6736(21)02724-0 URL pmid: 35065702
[3]	Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond), 2017, 49(3):161-169. doi:10.1080/23744235.2016.1262059. doi: 10.1080/23744235.2016.1262059 URL
[4]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[5]	Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis, 2019, 19(8): 903-912. doi:10.1016/S1473-3099(19)30307-X. doi: S1473-3099(19)30307-X URL pmid: 31281059
[6]	Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015, 3(12):963-972. doi:10.1016/S2213-2600(15)00458-0. doi: 10.1016/S2213-2600(15)00458-0 URL pmid: 26597127
[7]	Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis, 2014, 58 (3): 381-391. doi:10.1093/cid/cit643. doi: 10.1093/cid/cit643 URL pmid: 24065336
[8]	Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis, 2016, 16(10):1193-1201. doi:10.1016/S1473-3099(16)30132-3. doi: S1473-3099(16)30132-3 URL pmid: 27342768
[9]	Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014, 383(9928):1572-1579. doi:10.1016/S0140-6736(14)60195-1. doi: 10.1016/S0140-6736(14)60195-1 URL pmid: 24671080
[10]	Mehra M, Cossrow N, Kambili C, et al. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int J Tuberc Lung Dis, 2013, 17(9):1186-1194. doi:10.5588/ijtld.12.0959. doi: 10.5588/ijtld.12.0959 URL pmid: 23827732
[11]	Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Latent tuberculosis infection: a guide for primary health care providers-Diagnosis of latent TB infection. Atlanta: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2020.
[12]	World Health Organization. WHO operational handbook on tuberculosis (Module 1-Prevention): tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[13]	Li R, Nordio F, Huang CC, et al. Two Clinical Prediction Tools to Improve Tuberculosis Contact Investigation. Clin Infect Dis, 2020, 71(8): e338-e350. doi:10.1093/cid/ciz1221. doi: 10.1093/cid/ciz1221 URL pmid: 31905406
[14]	Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis, 2017, 17(11):1190-1199. doi:10.1016/S1473-3099(17)30447-4. doi: S1473-3099(17)30447-4 URL pmid: 28827142
[15]	World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015.
[16]	Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis, 2017, 64(12):1670-1677. doi:10.1093/cid/cix208. doi: 10.1093/cid/cix208 URL pmid: 28329197
[17]	Gupta A, Swindells S, Kim S, et al. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis, 2020, 70(3):425-435. doi:10.1093/cid/ciz235. doi: 10.1093/cid/ciz235 URL pmid: 30942853
[18]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management background document on the 2019 revision. Geneva: World Health Organization, 2019.
[19]	Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009—2012. Int J Tuberc Lung Dis, 2014, 18(8): 912-918. doi:10.5588/ijtld.13.0028. doi: 10.5588/ijtld.13.0028 URL
[20]	World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[21]	Holland DP, Sanders GD, Hamilton CD, et al. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One, 2012, 7(1): e30194. doi:10.1371/journal.pone.0030194. doi: 10.1371/journal.pone.0030194 URL
[22]	Fox GJ, Oxlade O, Menzies D. Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. Am J Respir Crit Care Med, 2015, 192(2):229-237. doi:10.1164/rccm.201501-0069OC. doi: 10.1164/rccm.201501-0069OC URL
[23]	Schluger NW. Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future? Am J Respir Crit Care Med, 2020, 202(8):1077-1078. doi:10.1164/rccm.202006-2488ED. doi: 10.1164/rccm.202006-2488ED URL
[24]	Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB mana-gement of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis, 2020, 92S:S15-S25. doi:10.1016/j.ijid.2020.01.042. doi: 10.1016/j.ijid.2020.01.042 URL
[25]	Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10): e93-e142. doi:10.1164/rccm.201909-1874ST. doi: 10.1164/rccm.201909-1874ST URL
[26]	Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med, 2018, 6(9):662-664. doi:10.1016/S2213-2600(18)30329-1. doi: 10.1016/S2213-2600(18)30329-1 URL pmid: 30191832
[27]	Gureva T, Turkova A, Yablokova E, et al. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int J Tuberc Lung Dis, 2022, 26(2):171-173. doi:10.5588/ijtld.21.0443. doi: 10.5588/ijtld.21.0443 URL pmid: 35086631
[28]	Huang CC, Becerra MC, Calderon R, et al. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2020, 202(8): 1159-1168. doi:10.1164/rccm.201908-1576OC. doi: 10.1164/rccm.201908-1576OC URL
[29]	Moore DA. What can we offer to 3 million MDRTB household contacts in 2016?. BMC Med, 2016, 14: 64. doi:10.1186/s12916-016-0610-x. doi: 10.1186/s12916-016-0610-x URL
[30]	中华人民共和国国家卫生健康委员会办公厅. 结核病预防控制工作技术规范(2020年版). 2020-04-02.

耐多药结核病患者密切接触者结核分枝杆菌潜伏感染的诊治现状与展望

Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	黄威, 沈银忠. 艾滋病合并结核病诊治中的关键问题[J]. 结核与肺部疾病杂志, 2022, 3(6): 431-436.
[2]	陈豪, 申晨. 重视儿童结核病的鉴别诊断[J]. 结核与肺部疾病杂志, 2022, 3(5): 353-357.
[3]	李静, 梁亚萍, 邹远妩, 张思琪, 郑见宝, 仵倩红. GeneXpert MTB/RIF检测粪便标本对肠结核的诊断价值[J]. 结核与肺部疾病杂志, 2022, 3(5): 382-387.
[4]	林慧敏, 符昱, 方章福, 谢佳星. 嗜酸性粒细胞哮喘的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 328-333.
[5]	何燕超, 揭志军. 综合医院活动性肺结核的早期筛查策略[J]. 结核与肺部疾病杂志, 2022, 3(4): 334-337.
[6]	张思琪, 李静, 仵倩红. 结核分枝杆菌扫描系统在结核病诊断中的应用价值[J]. 结核与肺部疾病杂志, 2022, 3(2): 170-172.
[7]	刘辉敏, 田瑶, 贝承丽, 傅满姣. 活动性肺结核免疫学检测技术应用现状及展望[J]. 结核与肺部疾病杂志, 2022, 3(1): 70-74.
[8]	周琳, 沈兴华. 皮肤结核一例[J]. 结核与肺部疾病杂志, 2022, 3(1): 85-86.
[9]	吴迪, 范欣欣, 沈建山, 林友飞, 陈晓红, 黄明翔, 陈力舟. 联合检测凝血筛查指标及D-二聚体对新型冠状病毒肺炎患者临床分型的诊断价值[J]. 结核与肺部疾病杂志, 2021, 2(4): 355-360.
[10]	邹霞丽, 阳海枚, 曾燃元, 伍子健, 唐琼, 李珏, 陈前友. 湖南省武冈市一起学校结核病聚集性疫情调查分析[J]. 结核与肺部疾病杂志, 2021, 2(4): 366-369.
[11]	中国防痨协会. 非活动性肺结核诊断及预防发病专家共识[J]. 结核与肺部疾病杂志, 2021, 2(3): 197-201.
[12]	张群成, 李向南, 徐志伟, 孙冠男, 杨会珍, 程东军, 张晓菊. 经电子气管镜冷冻肺活检在肺外周结节诊断中的价值[J]. 结核与肺部疾病杂志, 2021, 2(3): 205-209.
[13]	崔凯, 张晓菊. 生物标志物用于良恶性肺结节鉴别诊断的研究进展[J]. 结核与肺部疾病杂志, 2021, 2(3): 273-276.
[14]	李静, 张燕, 仵倩红. 非痰液样本结核分枝杆菌游离DNA检测在结核病诊断中的研究进展基金项目:陕西省卫生健康科研项目(2021D027)[J]. 结核与肺部疾病杂志, 2021, 2(3): 277-282.
[15]	姜游力, 张培泽, 邓国防, 陈敬芳. 结核病患者诊断延迟及其影响因素研究进展[J]. 结核与肺部疾病杂志, 2021, 2(3): 289-293.